Mesoblast Completes Treatment in Phase 3 Low Back Pain Trial
New York, USA / Melbourne, Australia August 17, 2026: Mesoblast Limited has completed patient treatment in its pivotal Phase...
inflammatory diseases
Advertisement
Tvardi Therapeutics Highlights TTI-109 Potential in Ulcerative Colitis
HOUSTON, Texas, August 12, 2026 Tvardi Therapeutics, Inc. announced that it will host a key opinion leader (KOL) webinar...
Photys Therapeutics and Polymed Begin Phase 1 Trial of PHT-776
WALTHAM, Massachusetts, and HANGZHOU, China, August 13, 2026 Photys Therapeutics, Inc. and Polymed Biopharmaceuticals, Inc. announced the initiation of...
Evommune Launches Phase 2b Trial of EVO756 for Migraine Prevention
PALO ALTO, Calif., & NEW YORK, July 30, 2026 Evommune announced that the first patient has been dosed in...
Incyte Secures EU Approval for Opzelura Cream in Atopic Dermatitis
WILMINGTON, Del., July 29, 2026 Incyte announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the...
Advertisements
NextCure and Avere Strengthen Oral IL-23 Development
SAN FRANCISCO, July 14, 2026 NextCure and privately held Avere Therapeutics have entered into a definitive all-stock merger agreement...
Aethlon Medical Reports Encouraging Hemopurifier Trial Results
SAN DIEGO, California, July 13, 2026 Aethlon Medical, Inc. has announced encouraging interim findings from the second patient cohort...
Keenova Publishes New Real-World Acthar Gel Autoimmune Data
DUBLIN, Ireland, July 13, 2026 Keenova Therapeutics plc has announced the publication of a new peer-reviewed real-world evidence study...
Santhera Reports Positive Phase 1 AGAMREE Data
Pratteln, Switzerland, July 1, 2026 Santhera Pharmaceuticals announced positive topline findings from a Phase 1 clinical study of AGAMREE®...
CalciMedica Receives FDA Clearance to Continue Auxora KOURAGE Trial
LA JOLLA, Calif., June 24, 2026 CalciMedica, Inc. announced that the U.S. Food and Drug Administration (FDA) has completed...
Advertisement
